tiprankstipranks
MEDIROM Healthcare Technologies (MRM)
NASDAQ:MRM
US Market

MEDIROM Healthcare Technologies (MRM) AI Stock Analysis

Compare
36 Followers

Top Page

MR

MEDIROM Healthcare Technologies

(NASDAQ:MRM)

38Underperform
MEDIROM Healthcare Technologies is currently struggling with significant financial and operational challenges. High leverage, declining revenues, and negative cash flow emphasize the need for strategic improvements. The technical indicators point to a bearish market sentiment, while valuation metrics suggest unattractiveness due to ongoing losses. The lack of clarity from recent earnings calls further adds to the uncertainty. Overall, the stock's outlook is constrained by these multiple adverse factors.

MEDIROM Healthcare Technologies (MRM) vs. S&P 500 (SPY)

MEDIROM Healthcare Technologies Business Overview & Revenue Model

Company DescriptionMEDIROM Healthcare Technologies Inc. provides holistic healthcare services in Japan. It operates in two segments, Relaxation Salon and Digital Preventative Healthcare. The Relaxation Salon segment owns and franchises relaxation salons, which provide finger-pressure style bodywork therapy, stretch therapy, and posture and joint alignment, as well as physical therapy elements; and various individual services, including anti-fatigue therapy, athletic support therapy, slim-down therapy, and reflexology. As of December 31, 2021, this segment operated 312 relaxation salons under the Re.Ra.Ku and Ruam Ruam brand. The Digital Preventative Healthcare segment offers government-sponsored Specific Health Guidance program, utilizing Lav, its internally developed on-demand health monitoring smartphone application; MOTHER Tracker for fitness applications; and preventative healthcare services utilizing its digital application and devices. MEDIROM Healthcare Technologies Inc. also operates Re.Ra.Ku College that offers continuing training for franchise owners, home office staff, and salon staff covering topics, such as customer service, salon operations, and relaxation techniques located in the Odaiba area in Tokyo. The company was formerly known as MEDIROM Inc. and changed its name to MEDIROM Healthcare Technologies Inc. in March 2020. MEDIROM Healthcare Technologies Inc. was incorporated in 2000 and is headquartered in Tokyo, Japan.
How the Company Makes MoneyMEDIROM Healthcare Technologies makes money through a combination of service fees from its relaxation and wellness studios, product sales, and digital health solutions. The company's primary revenue stream comes from its network of Re.Ra.Ku studios, where customers pay for various wellness services such as body treatments and fitness consultations. Additionally, MEDIROM generates revenue through the sale of health-related products and digital services, including wellness apps and devices that help users track and manage their health. The company may also engage in partnerships with corporate clients and other healthcare providers to expand its service offerings and reach, contributing to its revenue.

MEDIROM Healthcare Technologies Financial Statement Overview

Summary
MEDIROM Healthcare Technologies is facing significant financial challenges, with declining revenues and persistent operational losses impacting profitability. The company's high leverage and negative cash flow position underline the need for strategic financial management to stabilize its financial health. Improving operational efficiency and reducing debt are critical for enhancing future financial performance.
Income Statement
45
Neutral
The company has experienced declining revenue with a negative revenue growth rate from 2022 to 2023. The gross profit margin stands at approximately 22.98% for 2023, indicating some ability to cover costs. However, the company is struggling with profitability, as evidenced by the negative EBIT and net profit margins due to significant operating losses. This reflects challenges in managing expenses relative to revenue, impacting overall profitability.
Balance Sheet
40
Negative
The balance sheet reveals a high debt-to-equity ratio, highlighting significant leverage. The equity ratio is low, suggesting limited shareholder equity relative to total assets. Furthermore, the return on equity is positive for 2023 due to a positive net income, but the high levels of debt increase financial risk. The company's ability to enhance its financial stability is contingent on reducing debt levels and improving equity.
Cash Flow
35
Negative
The cash flow statement indicates challenges in cash management, as reflected by negative free cash flow. The operating cash flow to net income ratio is negative, signaling inefficiencies in converting net income into cash. A reduction in capital expenditures could improve free cash flow. The company's negative free cash flow growth rate from 2022 to 2023 is concerning.
Breakdown
TTMDec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Income StatementTotal Revenue
7.06B6.83B6.95B5.41B3.34B3.91B
Gross Profit
1.47B1.57B1.90B1.42B428.95M950.76M
EBIT
-717.99M-391.58M96.97M-395.38M-639.59M78.90M
EBITDA
-370.14M310.08M281.02M-269.13M-577.30M125.07M
Net Income Common Stockholders
-111.71M115.05M148.97M-990.73M-539.17M17.34M
Balance SheetCash, Cash Equivalents and Short-Term Investments
605.95M106.85M605.95M377.12M1.47B552.14M
Total Assets
6.75B6.85B6.75B5.75B5.71B4.76B
Total Debt
2.46B3.65B2.46B2.04B1.90B1.66B
Net Debt
1.86B3.54B1.86B1.67B463.82M1.15B
Total Liabilities
6.81B6.63B6.81B5.96B5.22B4.16B
Stockholders Equity
-59.38M210.88M-59.38M-208.34M491.26M600.06M
Cash FlowFree Cash Flow
-905.71M-767.58M-806.44M-652.88M-439.98M464.00K
Operating Cash Flow
-807.42M-631.74M-685.70M-557.23M-366.42M7.87M
Investing Cash Flow
259.00M-328.58M580.44M-83.94M-139.60M-37.93M
Financing Cash Flow
575.34M461.21M340.10M-427.95M1.43B331.99M

MEDIROM Healthcare Technologies Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.37
Price Trends
50DMA
0.73
Negative
100DMA
1.35
Negative
200DMA
2.49
Negative
Market Momentum
MACD
-0.11
Positive
RSI
23.72
Positive
STOCH
11.98
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MRM, the sentiment is Negative. The current price of 0.37 is below the 20-day moving average (MA) of 0.53, below the 50-day MA of 0.73, and below the 200-day MA of 2.49, indicating a bearish trend. The MACD of -0.11 indicates Positive momentum. The RSI at 23.72 is Positive, neither overbought nor oversold. The STOCH value of 11.98 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MRM.

MEDIROM Healthcare Technologies Risk Analysis

MEDIROM Healthcare Technologies disclosed 60 risk factors in its most recent earnings report. MEDIROM Healthcare Technologies reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

MEDIROM Healthcare Technologies Peers Comparison

Overall Rating
UnderperformOutperform
Sector (59)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
EHEHC
72
Outperform
$10.20B22.7124.52%0.63%11.91%28.47%
CHCHE
70
Outperform
$9.01B30.9427.12%0.31%7.37%11.17%
65
Neutral
$3.04B71.303.93%5.01%
64
Neutral
$1.80B23.368.78%9.06%10.68%
64
Neutral
$740.76M18.888.25%2.65%3.34%
59
Neutral
$12.17B11.04-1.10%3.77%1.26%-19.70%
MRMRM
38
Underperform
$1.82M54.56%-7.60%-118.80%
* Consumer Cyclical Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
MRM
MEDIROM Healthcare Technologies
0.37
-5.63
-93.83%
ADUS
Addus Homecare
98.93
-3.66
-3.57%
AMED
Amedisys
92.84
0.22
0.24%
CHE
Chemed
618.56
-13.09
-2.07%
HCSG
Healthcare Services
10.07
-2.32
-18.72%
EHC
Encompass Health
101.28
19.66
24.09%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.